TITLE:
Trying to Explain the Theoretical Basis of Traditional Chinese Medicine “Huashi Baidu Fang” in the Treatment of Coronavirus Disease 2019 with Western Medical Theory: A Review
AUTHORS:
Dandan Song, Hualiang Chen
KEYWORDS:
Huashi Baidu Fang, COVID-19, COPD, Gastrointestinal Inflammation
JOURNAL NAME:
Advances in Bioscience and Biotechnology,
Vol.11 No.9,
September
17,
2020
ABSTRACT: Purpose: This work is aimed to explain the theoretical basis
of “Huashi Baidu Fang” in the treatment of coronavirus disease 2019 (COVID-19) with western medical theory. Methods: We analyze the “Diagnosis and Treatment Protocol for COVID-19 (Version 1 to Version
7)” made by China, “Clinical management of severe acute respiratory infection
when novel coronavirus (2019-nCoV) infection is
suspected—Interim guidance” made by World Health Organization (WHO), “Therapeutic
Guidelines: Respiratory (Version 5)”, “Therapeutic Guidelines: Gastrointestinal
(Version 5)” and “Therapeutic Guidelines: Antibiotic (Version 15)” published by
Australia, and the origin of classical prescription of “Huashi Baidu Fang”: “Shanghanlun
(Treatise on Febrile Diseases)”, “Jinkui Yaolue (Synopsis of Golden Chamber)”
and “Wenyi Lun (The Epidemic Febrile Disease)”. We search the dictionary of
traditional Chinese medicine (Version II) manually. And we search literatures
from 2001 to 2020 on Wiley online library. We conduct a comparative study among
the symptoms of TCM formulations in “Huashi Baidu Fang”, the pathogenesis and
clinical manifestation of COVID-19 and COPD with acute gastrointestinal
inflammation. And we carry out pharmacological inquiry of “Huashi Baidu Fang”. Results: The clinical manifestations of respiratory symptoms and gastrointestinal tract
of syndrome of lung obstruction due to epidemic toxin and acute exacerbation of
COPD are almost the same; The formulations used in “Huashi Baidu Fang” are
consistent with the pharmacological activity of the drug recommended in the
Therapeutic Guidelines. Conclusion: “Huashi Baidu Fang” may play a
positive role in COVID-19.